Gene expression profiling and expanded immunohistochemistry tests for guiding adjuvant chemotherapy decisions in early breast cancer management: MammaPrint, Oncotype DX, IHC4 and Mammostrat (DG10)

NICE have evaluated the relative benefits of Oncotype DX, Mammaprint, IHC4 and Mammostat in guiding the use of adjuvant chemotherapy for patients with hormone receptor positive, lymph node negative, HER2 negative breast cancer

Classifications: Adjuvant & Neoadjuvant Treatment

Keywords: Gene Expression Profiling